Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Therapeutic equivalence of Travoprost PR vs Travatan in glaucoma or ocular hypertension
2011-005419-10Phase 3Completed
- Sponsor
- PHT Corporation
- Start
- Mar 2012
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of travoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by PHT Corporation. Primary endpoint: Change in intraocular pressure at 12 weeks. Started Mar 2012; status: completed.
02
Drugs
travoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on 2011-005419-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005419-10.